By Kelly Cloonan

Praxis Precision Medicines said vormatrigine, a treatment it is developing for certain seizures and epilepsy, did not meet its primary endpoint in a recent trial.

The biopharmaceutical company said Monday it is now pausing enrollment in the study to reassess the program and consider modifications.

The Phase 2/3 trial evaluated the safety and efficacy of vormatrigine in adults with focal onset seizures who are concurrently taking at least one but no more than three anti-seizure medications. The study's primary endpoint was the percent change in monthly seizure frequency from baseline.

However, the study met a secondary measure for a 50% response rate. Additionally, seizure reduction was more pronounced during the second half of the study, when patients received a higher dose, the company said.

"While the results for POWER1 were not what we hoped for, we are encouraged by the signal we saw on the higher dose arm, the low discontinuation rate and solid safety profile," Chief Executive Marcio Souza said.

Praxis is developing vormatrigine as a once-daily, oral treatment for adult focal onset seizures and generalized epilepsy. Vormatrigine is a small molecule that targets the hyperexcitable state of sodium-channels in the brain, the company said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 01, 2026 16:37 ET (20:37 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.